Novo Nordisk A/S (NVO) Earnings Call Analysis

NYSE · Unknown · Unknown

17/25

Growth 3 Margin 2 Expansion 5 Platform 2 Financial 5

latest quarter score

Earnings Reports

17
Novo Nordisk (NVO) Q2 2026: GLP-1 Obesity Franchise Drives 16% Growth as Pill Launches Expand Market Reach
August 05, 2026
17
Novo Nordisk (NVO) Q4 2025: Obesity Pill Launch Drives 134% Wegovy Growth, But 2026 Guides to Double-Digit U.S. Decline
June 15, 2026
17
Novo Nordisk (NVO) Q1 2026: Obesity Care Sales Jump 22% as Oral Wegovy Redefines Category
May 06, 2026
19
Novo Nordisk (NVO) Q3 2025: 9,000 Job Cuts Unlock DKK 8B for Obesity and Diabetes Focus
November 05, 2025
16
Novo Nordisk (NVO) Q2 2025: CapEx Climbs 49% as Supply Expansion Targets Global GLP-1 Demand
August 06, 2025
19
Novo Nordisk (NVO) Q1 2025: Strong 18% Growth as GLP-1 Compounding Clouds U.S. Outlook
June 10, 2025

Browse all companies